Applications and prospects of cryo-EM in drug discovery

Mil Med Res. 2023 Mar 6;10(1):10. doi: 10.1186/s40779-023-00446-y.

Abstract

Drug discovery is a crucial part of human healthcare and has dramatically benefited human lifespan and life quality in recent centuries, however, it is usually time- and effort-consuming. Structural biology has been demonstrated as a powerful tool to accelerate drug development. Among different techniques, cryo-electron microscopy (cryo-EM) is emerging as the mainstream of structure determination of biomacromolecules in the past decade and has received increasing attention from the pharmaceutical industry. Although cryo-EM still has limitations in resolution, speed and throughput, a growing number of innovative drugs are being developed with the help of cryo-EM. Here, we aim to provide an overview of how cryo-EM techniques are applied to facilitate drug discovery. The development and typical workflow of cryo-EM technique will be briefly introduced, followed by its specific applications in structure-based drug design, fragment-based drug discovery, proteolysis targeting chimeras, antibody drug development and drug repurposing. Besides cryo-EM, drug discovery innovation usually involves other state-of-the-art techniques such as artificial intelligence (AI), which is increasingly active in diverse areas. The combination of cryo-EM and AI provides an opportunity to minimize limitations of cryo-EM such as automation, throughput and interpretation of medium-resolution maps, and tends to be the new direction of future development of cryo-EM. The rapid development of cryo-EM will make it as an indispensable part of modern drug discovery.

Keywords: Artificial intelligence (AI); Cryo-electron microscopy (cryo-EM); Drug discovery; Drug repurposing; Fragment-based drug discovery; Proteolysis targeting chimeras; Structure-based drug design.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Artificial Intelligence*
  • Cryoelectron Microscopy
  • Drug Discovery*
  • Humans
  • Proteolysis Targeting Chimera
  • Quality of Life

Substances

  • Proteolysis Targeting Chimera